Mounjaro for PCOS: What the Evidence Shows and How to Get It

Mounjaro is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.

Active ingredient: tirzepatide
How it is taken: weekly injection
Approved for: Type 2 diabetes and heart risk
Best result (SURMOUNT-1): 20.9% weight loss

A quick Mounjaro overview

How long it remains in the body

About 5 days is the half-life. After 5 d, half is gone; five half-lives (25 d) leave about 3%.

Weight loss in the main trial

For type 2 diabetes, SURPASS-1 ran 40 weeks: 7.8 kg lost versus 1 kg on placebo.

Price as time passes

Prices each month are shown in US dollars, covering list price and self-pay offers taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, pricinginfo.lilly.com.

Who qualifies?

Mounjaro: who qualifies
Who sets the rule	Who qualifies
FDA label	When used with diet and exercise, it lowers blood sugar in adults and children 10 and older with type 2 diabetes.
FDA label	For adults with type 2 diabetes who are at high risk, it lowers the risk of heart attack, stroke, or heart-related death.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a 6-month diet and activity program comes first

Sources: FDA label (DailyMed) and aetna.com.

Trial results for PCOS

Among these trials, none enrolled just people with polycystic ovary syndrome (PCOS). The participants were adults who had obesity or overweight without diabetes, or obesity without type 2 diabetes.

Trials that tested the same ingredient (tirzepatide)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SURMOUNT-1	Zepbound	Adults with obesity or overweight, without diabetes	72 weeks	2,539	20.9% weight loss	3.1% on placebo
SURMOUNT-5	Zepbound	Adults with obesity, without type 2 diabetes	72 weeks	751	20.2% weight loss	Not listed

Sources for both studies: SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-5 (PubMed).

What is different because of PCOS?

Mounjaro: what its label says about polycystic ovary syndrome (PCOS)
What changes	What the label says
Hypoglycemia When Combined with Insulin Secretagogues or Insulin	Low blood sugar is more likely when you use this medicine with insulin or a sulfonylurea. Those doses may need to be lowered.
Taken with birth control pills	For a while, this medicine may reduce how well birth control pills work. After starting it and after every dose increase, add a barrier method or use a non-oral method.

These FDA labels say: FDA label (DailyMed).

These warnings appear in the FDA DailyMed label.

Insurance coverage and PCOS

Medicare Part D does not cover a GLP-1 used only for weight loss.

For weight-loss GLP-1s covered by Medicaid, you normally need prior authorization.

Sources: humana.com, KFF.

Alternatives for PCOS

GLP-1 medicines and polycystic ovary syndrome (PCOS)
Medicine	For PCOS	How it is taken	Trial result
Mounjaro	Not a listed use	weekly injection	Not listed
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed